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Abstract: Osteogenesis imperfecta (OI) comprises a genetically heterogeneous group of skeletal fragility
diseases. Here, we report on five independent families with a progressively deforming type of OI, in
whom we identified four homozygous truncation or frameshift mutations in MESD. Affected individuals
had recurrent fractures and at least one had oligodontia. MESD encodes an endoplasmic reticulum (ER)
chaperone protein for the canonical Wingless-related integration site (WNT) signaling receptors LRP5
and LRP6. Because complete absence of MESD causes embryonic lethality in mice, we hypothesized
that the OI-associated mutations are hypomorphic alleles since these mutations occur downstream of
the chaperone activity domain but upstream of ER-retention domain. This would be consistent with
the clinical phenotypes of skeletal fragility and oligodontia in persons deficient for LRP5 and LRP6,
respectively. When we expressed wild-type (WT) and mutant MESD in HEK293T cells, we detected WT
MESD in cell lysate but not in conditioned medium, whereas the converse was true for mutant MESD. We
observed that both WT and mutant MESD retained the ability to chaperone LRP5. Thus, OI-associated
MESD mutations produce hypomorphic alleles whose failure to remain within the ER significantly reduces
but does not completely eliminate LRP5 and LRP6 trafficking. Since these individuals have no eye
abnormalities (which occur in individuals completely lacking LRP5) and have neither limb nor brain
patterning defects (both of which occur in mice completely lacking LRP6), we infer that bone mass
accrual and dental patterning are more sensitive to reduced canonical WNT signaling than are other
developmental processes. Biologic agents that can increase LRP5 and LRP6-mediated WNT signaling
could benefit individuals with MESD-associated OI.
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Osteogenesis imperfecta (OI) comprises a genetically heterogeneous group of skeletal fragility diseases. Here, we report on five indepen-
dent families with a progressively deforming type of OI, in whomwe identified four homozygous truncation or frameshift mutations in
MESD. Affected individuals had recurrent fractures and at least one had oligodontia.MESD encodes an endoplasmic reticulum (ER) chap-
erone protein for the canonicalWingless-related integration site (WNT) signaling receptors LRP5 and LRP6. Because complete absence of
MESD causes embryonic lethality in mice, we hypothesized that the OI-associated mutations are hypomorphic alleles since these muta-
tionsoccurdownstreamof thechaperoneactivitydomainbutupstreamofER-retentiondomain.Thiswouldbe consistentwith theclinical
phenotypes of skeletal fragility and oligodontia in persons deficient for LRP5 and LRP6, respectively. When we expressed wild-type (WT)
andmutantMESD inHEK293Tcells,wedetectedWTMESDincell lysatebutnot in conditionedmedium,whereas theconversewas true for
mutantMESD.Weobserved that bothWTandmutantMESD retained the ability to chaperoneLRP5. Thus,OI-associatedMESDmutations
produce hypomorphic alleles whose failure to remain within the ER significantly reduces but does not completely eliminate LRP5 and
LRP6 trafficking. Since these individualshaveno eye abnormalities (whichoccur in individuals completely lackingLRP5) andhaveneither
limb nor brain patterning defects (both of which occur in mice completely lacking LRP6), we infer that bone mass accrual and dental
patterning are more sensitive to reduced canonical WNT signaling than are other developmental processes. Biologic agents that can in-
crease LRP5 and LRP6-mediated WNT signaling could benefit individuals withMESD-associated OI.
Osteogenesis imperfecta (OI) is agroupof inheriteddisorders
characterized by bone fragility. Clinical severity ranges from
non-deforming to progressively deforming to neonatally le-
thal.1 At present, mutations in 19 different genes have been
associatedwithOI:COL1A1 (MIM: 120150),COL1A2 (MIM:
120160), IFITM5 (MIM: 614757), BMP1 (MIM: 112264),
CREB3L1 (MIM: 616215), CRTAP (MIM: 605497), FKBP10
(MIM: 607063), MBTPS2 (MIM: 300294), P3H1 (MIM:
610339), PLOD2 (MIM: 301865), PPIB (MIM: 123841),
SEC24D (MIM: 607186), SERPINF1 (MIM: 172860),
SERPINH1 (MIM: 600943), SP7 (MIM: 606633), SPARC
(MIM: 182120), TENT5A (MIM: 611357), TMEM38B (MIM:
611236),WNT1 (MIM:164820).85%ofOIcasesarecaused
by mutations in one of the two genes that encode type 1
collagen, COL1A1 or COL1A2. Extra-skeletal manifestations
seen in individualswithOI, suchasblue sclerae, dentinogen-
esis imperfecta, and ligamentous laxity, depend upon the
specific gene that ismutated and thenatureof themutation.
Here we report the discovery of an additional
autosomal-recessive OI-associated gene (MESD, mesoderm
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pital das Clı́nicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, 05403-000, Brazil; 4Instituto de Biociências da Universidade de São
Paulo, São Paulo, 05508-090, Brazil; 5Institute of Human Genetics, University Hospital of Cologne, 50931 Cologne, Germany; 6Faculty of Medicine, Uni-
versity of Cologne, 50931 Cologne, Germany; 7Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology, University Hospital of Co-
logne, 50931 Cologne, Germany; 8Medical Genetics Unit, Hospital Pediátrico de Coimbra, Centro Hospitalar e Universitário de Coimbra, 3000-602 Coim-
bra, Portugal; 9Department of Clinical Genetics, St Michael’s Hospital, University Hospitals Bristol, BS1 3NU, Bristol, UK; 10Skeletal Dysplasia Group,
Department of Medical Genetics, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, 13083-887, Brazil; 11Hospital das Clı́nicas
da Faculdade deMedicina da Universidade Federal deMinas Gerais, Belo Horizonte 30130100, Brazil; 12Division of Genetics, Children’s Hospital, University
of Freiburg, 79106 Freiburg, Germany; 13University Clinic of Genetics, Faculty of Medicine, University of Coimbra, 3000-531 Coimbra, Portugal; 14Univer-
sity Clinic of Pediatrics, Faculty of Medicine, University of Coimbra, 3000-531 Coimbra, Portugal; 15Unidade de Endocrinologia, Instituto da Criança do
Hospital das Clı́nicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, 05403-000, Brazil; 16Institute of Human Genetics, University Hos-
pital Halle, Martin Luther University Halle-Wittenberg, 06112 Halle, Germany; 17Connective Tissue Unit, Division of Metabolism, University Children’s
Hospital Zurich, 8032 Zurich, Switzerland; 18Division of Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, Bern
University Hospital, CH-3010 Bern, Switzerland; 19Department of Pediatrics, University Hospital Cologne, 50931 Cologne, Germany; 20Clinic I of Internal
Medicine, University Hospital Cologne, 50931 Cologne, Germany; 21Cologne Center for Genomics, University of Cologne, 50931 Cologne, Germany;
22Medical Faculty of the University of Magdeburg, 39120 Magdeburg, Germany; 23Cluster of Excellence, Multiscale Bioimaging: from Molecular Machines
to Networks of Excitable Cells (MBExC), University of Göttingen, 37073 Göttingen, Germany
24These authors contributed equally to this work
25These authors contributed equally to this work
*Correspondence: bernd.wollnik@med.uni-goettingen.de
https://doi.org/10.1016/j.ajhg.2019.08.008.
836 The American Journal of Human Genetics 105, 836–843, October 3, 2019
 2019 American Society of Human Genetics.
Figure 1. Clinical and Radiological Features of Individuals with MESD Mutations
(1) Individual 1 from Brazil (Family 1 IV-5)
(1A–1B) Facial dysmorphic features include bluish sclerae, mid-face hypoplasia, arched eyebrows, tented upper lip; also note tracheos-
tomy, narrow chest, and rhizomelia; posteriorly rotated ears.
(1C–1D) Long fingers with adducted thumbs and contractures of the fifth digits.
(1E) Radiograph of left hand showing long, tapering fingers.
(1F–1G) Fracture of left ulna and radius at 5 months, healing with callus formation.
(1H) Radiograph of chest at 5 months showing bell-shaped, narrow chest with multiple (healing) rib fractures.
(2) Individual 2 from Turkey (Family 2 IV-1)
(2A–2B) Facial dysmorphic features include tall forehead, arched eyebrows with sparse lateral thirds, micrognathia, posteriorly rotated
ears, widely spaced teeth, and oligodontia.
(2C) Radiograph of left hand at 8 months showing long, tapering fingers.
(2D) Chest radiograph at 5 months showing bell-shaped thorax, thin ribs with healing posterior rib fractures.
(2E) Fracture of the left femur at age 4 years, post-surgical rodding.
(3) Individual 3 from Portugal (Family 3 V-2)
(3A–3C) Facial dysmorphic features include triangular facies, arched eyebrows, left convergent strabismus, midface hypoplasia, thin up-
per lip, pointed chin, widely spaced teeth, and oligodontia.
(3D) Hands showing long fingers with mild contractures.
(3E) Feet showing 2-3 partial cutaneous syndactyly with overlapping toes.
(3F–3G) Chest radiographs at 6 months and 12 years, respectively, showingmultiple rib fractures and progressive scoliosis with vertebral
compression fractures.
(3H–3I) Upper limb radiographs showing right and left humeral fractures, respectively.
(3J) Right knee at age 8 years, showing signs of cyclical pamidronate therapy, rodding of the tibia, and very gracile fibula.
(3K) Aged 16 years, thin femurs with bilateral rodding of the femoral shafts post-fracture.
(3L) Lateral spinal radiographs at 12 years, showing osteopenia, progressive vertebral compression fractures, and spinal fixation.
(4) Individual 4 from Brazil (Family 4 II-2)
(legend continued on next page)
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development gene, previously called MESDC2 [MIM:
607783]); we describe clinical findings in five affected
individuals from five independent, unrelated families;
and we provide data that support the likelihood that OI-
associated MESD mutations produce hypomorphic alleles
rather than complete loss-of-function alleles. This study
was conducted in accordance with the Helsinki Declara-
tion and was approved by the ethics committee of the Uni-
versity of Cologne, Germany and the ethics committee of
the University Medical Center Göttingen, Germany. All
guardians signed informed consent for the molecular anal-
ysis, for publication of the results and corresponding clin-
ical information, including clinical photographs, and for
skin biopsies, where applicable.
Individuals who participated in this study had been clin-
ically diagnosed with a progressive deforming form of OI
(Figure 1); radiographic findings in all included osteopenia,
skeletal deformity, healed fractures, and newly-acquired
fractures. All affected individuals were offspring of consan-
guineous unions and had no prior family history of skel-
etal fragility. We performed whole-exome sequencing in
order to simultaneously interrogate all known OI-associ-
ated genes. We used either the NimbleGen SeqCap EZ
Human Exome Library kit (Roche NimbleGen) or the Agi-
lent Sure Select Human All Exon V6 kit (Agilent Technolo-
gies) for exome capture. Library preparation, sequencing,
and data analysis were performed as previously
described.2 Because of parental consanguinity, auto-
somal-recessive inheritance was considered likely, so for
further study, we prioritized homozygous exonic and/or
splicing variants whose reference population frequencies
were <1% in gnomAD and ABraOM or <5% in in-house
controls.
None of the affected individuals had likely pathogenic
variants in any of the 19 genes which, when mutated,
are known to cause OI. Instead, the affected individuals
were each homozygous for a mutation in the third and
final exon of MESD (GenBank: NM_015154.1), which is
located downstream of the chaperone domain and up-
stream of the ER-retention domain (Table 1; Figure 2).
These MESD variants were heterozygous in each parent
and were not common polymorphisms in the Exome
Variant Server, 1000 genomes, dbSNP, ExAC, or gnomAD
databases. We found four different MESD mutations in
the five affected individuals (c.607_611del [p.Thr203A-
lafs*26], c.631_632del [p.Lys211Glufs*19], c.632dupA
[p.Lys212Glufs*19] found in two persons, and c.676C>T
[p.Arg226*]). Notably, there are no high-quality loss-of-
function variants annotated for MESD in the gnomAD
database, while 7.9 such variants were calculated to be ex-
pected according to constraint metrics, indicating a high
degree of loss-of-function intolerance of the gene (pLI ¼
0.91, observed/expected ratio ¼ 0).
Salient clinical features in the individuals with MESD
mutations are summarized in Table 1, and comprehensive
clinical information is provided in the case reports in the
Supplemental Data. Two individuals died from respiratory
insufficiency before 18 months of age. The oldest affected
individuals, when assessed at the ages of 10 years and 16
years, respectively, were non-ambulatory. Bluish sclerae
were noted in the youngest individuals, but not in the
older ones. None had dentinogenesis imperfecta, but the
three older individuals had disorganized dentition and/
or oligodontia (Figure 1). Global developmental delay or
evidence of intellectual disability (ID) was present in three
individuals (Table 1).
MESD mutations have not previously been associated
with a human disease phenotype. In mice, homozygous
loss-of-function Mesd mutations cause embryonic lethality
during gastrulation.3 Mouse embryos homozygous for
deletions spanning Mesd can already be distinguished
from WT embryos at embryonic day E7.5, when they
show lack of mesoderm and failure to form a primitive
streak.3–5 These embryos do not survive beyond E11.5.3
Functional studies of MESD and its Drosophila ortholog,
Boca, indicate that these proteins are endoplasmic reticu-
lum (ER) chaperones for canonical Wingless-related integra-
tion site (WNT) signaling receptors (LRP5 and LRP6
in mammals and Arrow in Drosophila).5,6 In the absence of
MESD, LRP5 and LRP6 cannot traffic to the cell surface.5–9
The likelihood that MESD mutations cause OI in these
five individuals is supported by prior research demon-
strating the importance of canonical WNT signaling in
skeletal development.2,10–18 Specifically, LRP5 loss-of-func-
tion mutations are seen in the autosomal-recessive skeletal
fragility disorder Osteoporosis-Pseudoglioma (OPPG) syn-
drome and in autosomal dominant juvenile osteopo-
rosis.10,11 Additionally, WNT1 loss-of-function mutations
have been found in autosomal-recessive OI and in domi-
nant early onset osteoporosis.2,12,13 Other data in support
of the importance of canonical WNT signaling in skeletal
development derive from human GWAS studies and from
(4A) He has minimal facial dysmorphic features, slightly upslanting palpebral fissures, and a pointed chin; sclerae are white; skeletal
deformity with rhizomelic shortening is noted.
(4B) Impression of long fingers with mild interphalangeal contractures.
(4C) Panorex radiograph showing disorganized dentition, abnormal premolars, and missing lower jaw teeth (numbers 31, 32, and 41).
(4D–4E) Radiographs showing osteopenia, narrow chest, thin ribs with fractures, scoliosis, and vertebral compression fractures.
(4F–4H) Radiographs showing skeletal deformity and evidence of fractures of the femoral necks and tibiae.
(5) Individual 5 from Brazil (Family 5 IV-1)
(5A–5C) Facial dysmorphic features include round face, prominent eyes with long lashes and epicanthic folds, small nose with bulbous
tip, tented upper lip, high and narrow palate, retrognathia, and posteriorly rotated ears; also note narrow thorax with inverted nipples,
rhizomelic shortening of limbs, and long fingers with contractures.
(5D–5F) Radiographs showing generalized osteopenia, multiple fractures (clavicles, ribs, left humerus, femur), narrow thorax, and
bowing of femurs bilaterally.
838 The American Journal of Human Genetics 105, 836–843, October 3, 2019
studies in mice with germline and conditional knockout
alleles of canonical WNT signaling pathway components.
For example, loci identified by GWAS for bone mineral
density and fracture risk include WNT pathway mem-
bers.14,15 Inmice, bone-forming osteoblasts fail to differen-
tiate when canonical WNT signaling is ablated.16–18
Table 1. Clinical Features of Individuals with Homozygous Mutations in MESD













country of origin Brazil Turkey Portugal Brazil Brazil
gender female male male male male
consanguinity yes yes yes yes yes
age at first visit
(years)
after birth 3 years, 4 months 4 years, 6 months 10 years 6 months
age at last visit
(years)
1 year, 5 months
(death)
8 years, 4 months 11 years, 1 months 12 years, 2 months 7 months (death)
age at start of
bisphosphonate
treatment
15 days 3 years, 5 months 3 years, 6 months 5 years not treated
age at end of
bisphosphonate
treatment







W ¼ 2,135 g (2.35 SD),
L ¼ 45 cm (1.93 SD)
(39 WG)
W ¼ 1,550 g (2.8 SD)
L ¼ 43 cm (2.58 SD)
(34 WG)
W ¼ 3,730 g (þ0.38 SD)
L ¼ 51 cm (þ0.38 SD)
(37 WG)
W ¼ 2,730 g (1.35 SD)
L ¼ 52 cm (þ0.76 SD)
(term)
W ¼ 2,465 g (1.73 SD)




yes no no no yes
age at first fracture
(months)
prenatal 11 months 24 months 24 months prenatal
color of sclera bluish white white white bluish
eye abnormalities NFA no no no no
dentinogenesis
imperfecta








NA NA NA yes NA
hypermobility
of joints




with a small left to
right shunt









yes yes (five fractures) yes (right clavicle 2
years left femur 3
years 6 months
right femur 4 years)





no yes (multiple fractures










yes yes yes yes yes
L ¼ length; NA ¼ not available; NFA ¼ not formally assessed; SD ¼ standard deviation; WG ¼ weeks of gestation; W ¼ weight
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Because embryonic lethality occurs in mice completely
lacking MESD3–5 or both LRP5 and LRP6,19 we hypothe-
sized that the MESD mutations responsible for human OI
represent hypomorphic rather than amorphic alleles.
Several lines of evidence support this speculation. First,
OI-associated MESD mutations occur in the last exon,
rather than throughout the gene, thereby making them
likely to escape nonsense-mediated mRNA decay. Second,
all mutations truncate or frameshift the protein after the
202nd amino acid residue, which is carboxy-terminal to
the protein’s chaperone activity domain.20 Third, the OI-
associated mutations all remove a highly conserved ER-
retention domain;5 the inability to retain or recycle
MESD in the ER could reduce the protein’s efficiency in
serving as a chaperone.
To test this hypothesis, we studied fibroblasts from Indi-
vidual 2 (Family 2 IV-1) and control fibroblasts, and we
expressed wild-type (WT) and mutant MESD in HEK293T
cells. We were able to RT-PCR amplify spliced MESD
mRNA transcripts from WT-derived and Individual
2-derived fibroblast cultures. Thus, at least oneMESDmuta-
tion does not cause nonsense-mediated mRNA decay
(Figure 3A). Since the other mutations reported here are
located in the same (and final) exon of MESD, likely the
same will hold true for them. Also, an antibody whose
epitope is near the amino-terminal domain of MESD and
should be able to recognize WT and OI-associated mutant
MESD only detected MESD in cell lysate from WT fibro-
blasts (Figure 3B); this is consistent with mutant MESD
failing to remain intracellular when its ER-retention
domain is lost. Because endogenous MESD levels can be
rate limiting when LRP5 or LRP6 is overexpressed,5 we per-
formed transient transfection assays to determine whether
mutant MESD retains an ability to chaperone LRP5. We
used a previously described FLAG-epitope-tagged mouse
Mesd expression construct that can chaperone human
LRP5 in HEK293T cells.21 We performed site-directed muta-
genesis to modify thisMesd construct to create a truncation
mutation (Quikchange Lightning Site-Directed Mutagen-
esis Kit, Agilent Technologies). The alteration p.Lys212* re-
tains the chaperone activity domain and deletes the ER-
retention domain, as do the OI-associated mutations
(Figure 2 lower panel). Because lack of the ER-retention
domain could allow mutant MESD to traffic outside the
cell, we then examined the cell lysates and conditionedme-
dium of transiently transfected HEK293T cells. In agree-
ment with what we previously observed in control and In-
dividual 2-derived fibroblasts, WT but not mutant MESD
was detected in the cell lysate. In conditioned medium,
only mutant and not WT MESD was detected (Figure 3C).
These findings are consistent with the mutant MESD being
synthesized but not retained within the ER.
Figure 2. Pedigrees of the Five MESD-Associated OI Individuals, Their MESD Mutations, and the Location of these Mutations in the
MESD Protein
Upper panel: Family pedigrees and mutations in MESD for each affected individual.
Lower panel: Alignment of humanMESDwith mouseMESD, showing important chaperone activity and ER-retention domains; the first
amino acid residues affected by the four different affected individual mutations are noted with red rectangles and the amino acid residue
converted to a termination codon in the mouse Mesd expression construct is asterisked.
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We next determined whether the mutant protein could
still chaperone LRP5. We co-expressed WT, or mutant,
MESD with a Myc-epitope-tagged human LRP5 that lacks
a transmembrane domain.21 Both WT and mutant MESD
increased the abundance of epitope-tagged LRP5 in the
conditioned medium (Figure 3D). Taken together, these
data indicate that mutantMESD retains the ability to chap-
erone and traffic LRP5, though it may do so less efficiently
than WT MESD because it fails to be retained in the ER.
The oligodontia, observed in Individual 4 for whom we
have panorex films, may distinguish MESD-associated OI
from other causes of OI. Reduced LRP6 signaling is the
likely cause of oligodontia in this individual because
oligodontia also occurs in persons who are heterozygous
for LRP6 loss-of-function mutations.22 It is interesting
that individuals with OI-associated MESD mutations do
not have the eye defects seen in individuals who have
the autosomal-recessive OPPG syndrome and who lack
LRP5. Given that individuals with MESD-associated OI
do not phenocopy humans or mice that are completely
deficient for either LRP5 or LRP6, it seems likely that
the skeletal fragility phenotype in those with MESD mu-
tations is due to partial reductions in LRP5 and LRP6
signaling. This mechanism would be consistent with
data from mice, in which partial reductions in LRP5
and LRP6 signaling affect bone mass without affecting
other organ systems.23 At present, we do not know the
relationship between the MESD mutation and the ID
we observed in several affected persons. These individ-
uals had no variants in known ID genes. Interestingly,
ID is also a variable clinical feature of WNT1-associated
recessive OI.24
In the individuals described here, we attempted to in-
crease bone strength and reduce deformity by treating
with bisphosphonates, which have been useful in other
types of OI. Unfortunately, we did not observe benefi-
cial effects in the four individuals treated (see Case Re-
ports in Supplemental Data). Bisphosphonates function
primarily to reduce bone catabolism, rather than to pro-
mote bone anabolism. Since the skeletal fragility in
these individuals is a likely consequence of low bone
formation due to reduced WNT signaling, therapies
that can enhance WNT signaling may have therapeutic
efficacy. In this regard, it should be noted that Evenity
(romozosumab-aqqg; Amgen) has recently gained FDA
approval for increasing bone formation and bone
mass in individuals with age-related osteoporosis. This
therapeutic monoclonal antibody works by neutralizing
sclerostin, an endogenous LRP5 and LRP6 inhibitor.
Sclerostin neutralization in the LRP5 knockout mouse
model of the OPPG syndrome produced significant in-
creases in bone mass and bone strength.25,26
This same response could occur in individuals with
MESD-associated OI.
In conclusion, we identifiedMESD as an additional locus
for autosomal-recessive OI. The likely mechanism of effect
Figure 3. Individual 2-Derived and Tran-
siently Transfected Cell Cultures Showing
That OI-Associated MESD Protein Is Ex-
pressed and Capable of Serving as a Chap-
erone for LRP5, but Unable to Be Retained
within Endoplasmic Reticulum of the Cell
(A) Agarose gel electrophoretic separation
and fluorescence staining of RT-PCR am-
plimers spanning from exon 1 to exon 3 ob-
tained from wild type (WT, control) and
MESD-associated OI (Individual 2) cultured
fibroblasts. Spliced MESD amplimers are de-
tected in both samples; spliced GAPDH am-
plimers serve as a positive control.
(B) Immunodetection of MESD following
SDS-PAGE in cell lysates from control and
Individual 2 fibroblasts. A polyclonal anti-
body that detects an epitope near the
amino-terminal domain of MESD should
recognize bothWTandmutantMESD. How-
ever, only WT MESD is present in the cell
lysate.
(C) Representative immuno-blot following
SDS-PAGE of FLAG epitope-tagged WT or
mutant (p.Lys212*) MESD in cell lysate and conditionedmedium from transiently transfected HEK293Tcells. WTMESD is only detected
in the cell lysate, whereas mutant MESD is only detected in the conditioned medium.
(D) Representative immuno-blots of the same membrane following SDS-PAGE using anti-myc antibody (for LRP5), anti-FLAG antibody
(for MESD), anti-beta actin antibody (as a loading control for the cell lysate), and a non-specific cross-reacting band (as a loading control
for the conditioned medium) of cell lysate and conditioned medium from HEK293T cells that were transiently transfected with expres-
sion vectors for myc-epitope tagged LRP5 (LRP5-myc), FLAG-epitope tagged WT MESD (MESD WT), or FLAG-epitope tagged mutant
MESD (MESD p.Lys212*). Note co-expression of LRP5-myc with either WTor mutantMESD increases the amount of immuno-detectable
LRP5 in cell lysate and in conditioned medium, compared to when LRP5-myc is expressed alone. Also note that mutant MESD becomes
detectable at low levels in cell lysate from HEK293T cells when transiently co-expressed with LRP5-myc. Mutant MESD is 13 amino acid
residues shorter than WT MESD, which is why it migrates faster during SDS-PAGE.
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for the four identified MESD truncating and frameshift
mutations is the lack of ER retention, which reduces but
does not eliminate the protein’s role as a chaperone for
the WNT receptors LRP5 and LRP6. However, since MESD
when bound to LRP5 can block WNT signaling,27 it is
possible that the abnormal trafficking of mutant MESD
outside of the cell causes a neomorphic effect. All five of
the individuals with MESD-associated OI have a progres-
sive deforming phenotype. Oligodontia may be a feature
that separates this type of OI from the other known causes;
however, too few individuals have been studied to reliably
draw this conclusion. MESD joins a list of other WNT
pathway components in which mutations can negatively
affect bone mass accrual and bone strength. Therapies
that enhance canonicalWNTsignaling in bonemay signif-
icantly benefit these individuals.
Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2019.08.008.
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